@WHO: WHO welcomes the announcement of a 🆕 voluntary licensing agreement between @ViiVHC and @MedsPatentPool for patents relating to long acting-cabotegravir (CAB-LA), an important prevention option to people for substantial risk of #HIV infection. 📌 https://t.co/awsJCfJ3X1 https://t.co/WhUWO8StCl

http://twitter.com/WHO
via IFTTT